Compare RCEL & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | RPID |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.5M | 204.3M |
| IPO Year | N/A | 2021 |
| Metric | RCEL | RPID |
|---|---|---|
| Price | $4.33 | $2.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.88 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 192.3K | 148.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | $17.17 | $19.12 |
| Revenue Next Year | $49.82 | $18.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $3.22 | $2.01 |
| 52 Week High | $7.12 | $4.94 |
| Indicator | RCEL | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 49.34 |
| Support Level | $4.02 | $2.36 |
| Resistance Level | $4.57 | $2.92 |
| Average True Range (ATR) | 0.28 | 0.13 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 42.75 | 55.10 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.